Meta-analysis: Adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer

Annals of Internal Medicine

Volumn 156, Issue 6, 2012, Pages

  Kiely, Belinda ^a   Stockler, Martin ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RISK; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOEMBOLISM; UTERUS CANCER;

EID: 84858319623     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-6-201202210-02004     Document Type: Article

References (1)

1. Burstein HJ, Prestrud AA, Seidenfeld J, et al; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784-3796.